What is it about?
The scientific requirements for the Innovative Medicines Initiative Open PHACTS consortium for the design of the Open Pharmacological Space information system built on the integration of compound-target-pathways-disease/phenotype data are outlined. Typical scientific competency questions provided by the consortium members are analyzed based on the underlying data concepts and data associations needed to answer the questions
Featured Image
Why is it important?
The overall goal of the Open PHACTS project is to deliver an open, integrated and sustainable chemistry, biology and pharmacology resource for drug discovery. The analysis of the questions asked by members of the consortium is pivotal to defining the needs of the platform
Read the Original
This page is a summary of: ChemProt: A Disease Chemical Biology Database, December 2013, Taylor & Francis,
DOI: 10.1201/b15631-9.
You can read the full text:
Resources
The OPen PHACTS website
The Open PHACTS Discovery Platform has been developed to reduce barriers to drug discovery in industry, academia and for small businesses. This is the primary website for the project.
Practical semantics in the pharmaceutical industry - the Open PHACTS project
Slideshare presentation by me at the ACS Meeting in Indianapolis. The talk focused on the EU-Open PHACTS initiative (openphacts.org), established to provide a unique public-private infrastructure for pharmaceutical discovery. The aims of this work will be described and how technologies such as just-in-time identity resolution, nanopublication and interactive visualisations are helping to build a powerful software platform designed to appeal to directly to scientific users
Applying linked data approaches to pharmacology: Architectural decisions and implementation
The architecture of the OPS platform is described focusing on seven design decisions that drove its development with the aim of informing others developing similar software in this or other domains. The utility of the platform is demonstrated by the variety of drug discovery applications being built to access the integrated data.
Contributors
The following have contributed to this page
